Ampersand Capital Partners
55 William StreetWellesley, MA 2481
Website: ampersandcapital.com
Firm Size
- Assets Under Management (AUM):$2.8 Billion
- Number of Funds:5
- Employees:32
- Firm Type:Private Equity
- Focus Areas:
Software & Technology
Manufacturing
Services
Healthcare
Description
Ampersand Capital Partners is a private equity firm headquartered in Wellesley, Massachusetts. The firm specializes in investing in middle-market companies primarily in the healthcare sector. With over $1 billion in assets under management, Ampersand focuses on businesses providing innovative products, technologies, and services to the healthcare industry. The firm takes a long-term perspective and aims to partner with management teams to drive growth and enhance value. Ampersand seeks to invest in companies with a strong market position, differentiated offerings, and potential for expansion through organic growth or strategic acquisitions. Ampersand has a deep understanding of the healthcare industry and utilizes its network and expertise to assist portfolio companies in achieving their strategic goals. The firm provides capital, operational support, and industry insights to help businesses accelerate their growth and navigate challenges. Since its inception in 1988, Ampersand has successfully invested in numerous healthcare companies, including medical products manufacturers, pharmaceutical services providers, and healthcare IT companies. The firm has a track record of delivering strong financial performance and generating favorable returns for its investors. Overall, Ampersand Capital Partners is a reputable private equity firm with a focus on the healthcare sector. With its expertise, resources, and collaborative approach, the firm aims to partner with promising companies and contribute towards the advancement of the healthcare industry.Latest News
Powered by
May 16, 2024: Ampersand Capital Partners Ranks #1 for Growth Capital Private Equity Performance by HEC Paris-DowJones
For the second consecutive year, Ampersand Capital Partners is ranked #1 globally by HEC Paris-DowJones for growth capital private equity performance. HEC Paris analyzed performance data from 106 Growth Capital firms and the 279 funds they raised between 2010 and 2019 with an aggregate equity volume of $172B .
Mar 19, 2024: Ampersand Capital Partners Acquires Biologos
Ampersand Capital Partners ("Ampersand"), a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, announced today the acquisition of Biologos LLC ("Biologos"), a full-service manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. The partnership with Ampersand will include investments to expand Biologos' capabilities, product offerings, and geographic reach to support its cell and gene therapy, biopharmaceutical, tissue processing, and animal health customers globally.
Nov 20, 2023: New Capital Strengthens ProtaGene's Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy Markets
ProtaGene, a leading global contract research organization (CRO) dedicated to advanced analytics for biologics and cell and gene therapies, today announced additional investment from Ampersand Capital Partners.
Nov 06, 2023: Ampersand Capital Partners Named to Inc.'s 2023 List of Founder-Friendly Investors
For the second consecutive year, Ampersand Capital Partners was named to Inc.'s 2023 Founder-Friendly Investors list, which honors the private equity and venture capital firms with the best track records partnering with entrepreneurs. The list honors investment firms that remain actively involved with the businesses in which they invest and that have earned the trust of the entrepreneurs they support.
Nov 02, 2023: Genezen Secures $18.5 Million in Growth Equity to Expand Viral Vector Development and Manufacturing Capabilities
Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced the closing of an $18.5 million follow-on growth equity investment led by Ampersand Capital Partners. The financing will accelerate Genezen's growth trajectory in retroviral, lentiviral and adeno-associated viral (AAV) vector manufacturing and support the execution of a robust pipeline of customer projects for innovators developing groundbreaking cell and gene therapies.
Jul 18, 2023: Preqin Ranks Ampersand Capital Partners as the Top Performing Private Equity Fund Manager and Top Performing Growth Fund Manager in the Americas
Ampersand Capital Partners was recently named by Preqin as the "Top Performing Private Equity Fund Manager" and the "Top Performing Growth Fund Manager" in the Americas. Winners were announced on June 29, 2023 , and the awards are based solely on objective data with winners selected based on consistency of performance.
Jun 12, 2023: NanoImaging Services Receives Growth Equity Investment from Ampersand Capital Partners
NanoImaging Services ("NIS"), the leading provider of cryo-electron microscopy ("cryo-EM") services to the pharmaceutical and biotechnology communities, announced today that it has received a growth equity investment from Ampersand Capital Partners. Members of the NIS management team joined Ampersand in the financing. The company will use this investment to support its worldwide growth initiatives, including expanding microscope capacity and adding complementary services to further serve the needs of existing and future customers.
May 22, 2023: Ampersand Capital Partners Ranked #1 on the 2022 HEC-DowJones Growth Capital Private Equity Performance Ranking
Ampersand Capital Partners is proud to be ranked as the #1 top performer globally in the first edition of the HEC Paris-DowJones Performance Ranking of Growth Capital Funds. For this ranking, HEC analyzed performance data for 208 growth capital firms and the 390 funds they raised between 2009 and 2018.